Science, the neurotechnology startup founded by former Neuralink president Max Hodak, is moving toward the implementation phase of its first human clinical trials. Following a series of regulatory updates and the recruitment of Yale’s Chair of Neurosurgery as a scientific adviser, the startup is positioning a vision that diverges sharply from the industry standard. While competitors like Synchron and Neuralink have prioritized "reading" brain signals to restore motor control, Science is developing its proprietary sensor as a therapeutic device designed to actively heal damaged neural tissue.
The strategic mandate for this inaugural trial is to validate the sensor’s ability to deliver targeted electrical stimulation to brain and spinal cord cells. By triggering the body’s natural recovery processes, the device aims to treat conditions resulting from trauma, stroke, and neurodegeneration. This shift from assistive to regenerative technology creates a distinct competitive moat in a sector that saw over $600 million in venture investment last year.
This move is a high-stakes play for market differentiation. By focusing on healing rather than just interfacing, Hodak is targeting an underserved patient demographic, including those with chronic spinal injuries and stroke-related tissue damage. The sensor—refined to rest on the cortex rather than penetrate it—aims to minimize the long-term tissue scarring that has historically limited the lifespan of brain implants. Success in this phase would likely trigger a significant valuation reset for the firm, which was last pegged at $1.5 billion.
